Jonathan E. Rosenberg, MD, on Clinical Implications of New Findings on Durvalumab Plus Olaparib for Stage IV Urothelial Cancer

Posted: Tuesday, March 8, 2022

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II results from the BAYOU trial as well as the potential benefits of combining a checkpoint inhibitor and a PARP inhibitor in the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma.